100 years post-insulin: immunotherapy as the next frontier in type 1 diabetes [0.03%]
胰岛素问世百年后的今天：免疫治疗将成为1型糖尿病的下一个制高点吗？
James A Pearson,Eoin F McKinney,Lucy S K Walker
James A Pearson
Type 1 diabetes (T1D) is an autoimmune disease characterised by T cell-mediated destruction of the insulin-producing β cells in the pancreas. Similar to other autoimmune diseases, the incidence of T1D is increasing globally. The discovery ...
A phase 1b open-label dose-finding study of ustekinumab in young adults with type 1 diabetes [0.03%]
乌司奴单抗治疗1型糖尿病的2期临床试验
Ashish K Marwaha,Samuel Chow,Anne M Pesenacker et al.
Ashish K Marwaha et al.
Objectives: We assessed the safety of ustekinumab (a monoclonal antibody used in psoriasis to target the IL-12 and IL-23 pathways) in a small cohort of recent-onset (
Sophie Curio,Gustav Jonsson,Sonja Marinović
Sophie Curio
Cancer immunotherapies have significantly improved patient survival and treatment options in recent years. Nonetheless, the success of immunotherapy is limited to certain cancer types and specific subgroups of patients, making the developme...
The clinical correlates of vaccine-induced immune thrombotic thrombocytopenia after immunisation with adenovirus vector-based SARS-CoV-2 vaccines [0.03%]
腺病毒载体新冠疫苗接种后出现的疫苗诱发免疫性血小板减少症的临床特点
Eleanor R Gaunt,Neil A Mabbott
Eleanor R Gaunt
We are at a critical stage in the COVID-19 pandemic where vaccinations are being rolled out globally, in a race against time to get ahead of the SARS-CoV-2 coronavirus and the emergence of more highly transmissible variants. A range of vacc...
Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors [0.03%]
接受免疫检查点抑制剂治疗的患者中他汀类药物非预期使用与骨骼肌病之间的关联
Zsofia D Drobni,Sean P Murphy,Raza M Alvi et al.
Zsofia D Drobni et al.
Objectives: Skeletal myopathies are highly morbid, and in rare cases even fatal, immune-related adverse events (irAE) associated with immune checkpoint inhibitors (ICI). Skeletal myopathies are also a recognized statin-as...
A glutamine 'tug-of-war': targets to manipulate glutamine metabolism for cancer immunotherapy [0.03%]
谷氨酰胺“拉锯战”：操控谷氨酰胺代谢以用于癌症免疫治疗的目标
Laura J Pallett,Sarah Dimeloe,Linda V Sinclair et al.
Laura J Pallett et al.
Within the tumour microenvironment (TME), there is a cellular 'tug-of-war' for glutamine, the most abundant amino acid in the body. This competition is most evident when considering the balance between a successful anti-tumour immune respon...
Type 2 immunity is maintained during cancer-associated adipose tissue wasting [0.03%]
2型免疫在癌症相关脂肪组织消耗过程中得以保持
Patrick J Lenehan,Assunta Cirella,Amiko M Uchida et al.
Patrick J Lenehan et al.
Objectives: Cachexia is a systemic metabolic disorder characterized by loss of fat and muscle mass, which disproportionately impacts patients with gastrointestinal malignancies such as pancreatic cancer. While the immunol...
Shane M O&#x;Carroll,Luke A J O&#x;Neill
Shane M O&#x;Carroll
The COVID-19 crisis has emphasised the need for antiviral therapies to combat current and future viral zoonoses. Recent studies have shown that immune cells such as macrophages are the main contributors to the inflammatory response seen in ...
Antonella Adami,John Maher
Antonella Adami
Immunotherapy of cancer using chimeric antigen receptor-engineered T-cells has transformed the management of selected haematological malignancies, triggering intense clinical trial activity in this arena. This article summarises trial activ...
Protective low-avidity anti-tumour CD8+ T cells are selectively attenuated by regulatory T cells [0.03%]
调节性T细胞选择性地抑制具有保护作用的低亲和力抗肿瘤CD8+t细胞
Gessa Sugiyarto,David Prossor,Osman Dadas et al.
Gessa Sugiyarto et al.
Objectives: Regulatory T cells (Treg) play a major role in the suppression of protective anti-tumour T cell responses. In the CT26 BALB/c murine model of colorectal carcinoma, Tregs differentially suppress responses to tw...